A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa

Summary

The purpose of this study is to determine whether administration of FCX-007 in addition to standard of care improves wound healing as compared to standard of care alone (control) in children, adolescents, and adults with Recessive Dystrophic Epidermolysis Bullosa. Funding Source - FDA OOPD

Timeline

Start

2020-06-09

Primary completion

2023-01-17

Completion

2037-07

Drugs

Indications